Iroko Pharmaceuticals to Participate in Small Business Administration’s Office of Advocacy Innovation Initiative Event

Osagie Imasogie Scheduled to Speak and Provide a Tour of the Iroko Headquarters for Chief Counsel for Advocacy Dr. Winslow Sargeant

PHILADELPHIA, September 19, 2013 — Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, will participate in the Small Business Administration’s (SBA) upcoming conference “Small Business and Government: Maximizing Entrepreneurship, Driving Innovation: A Multiregion-Multicity Conversation with the Chief Counsel for Advocacy.” The four-day conference will bring together Regional Advocates and federal agency representatives to listen to small businesses, innovators and other participants in the entrepreneurial ecosystem. Mr. Osagie Imasogie, Iroko Chairman and Senior Managing Partner of Phoenix IP Ventures, will speak at the event on September 25, and following the conference on that day, Chief Counsel for Advocacy Dr. Winslow Sargeant – a federally-appointed small business advocate – and other conference participants will join Mr. Imasogie on a tour of the Iroko headquarters in Philadelphia’s Navy Yard complex.

“The success of small businesses is critical to the future of our economy, and it is a true honor to work with the Small Business Administration to identify best practices that can help advance individual companies, as well as the local economy,” said Mr. Imasogie. “Iroko was built on the notion that small can be big, a concept embodied by our pipeline of submicron NSAIDs that aims to address an unmet need in pain management by providing effective pain relief at lower doses.”

The meeting will commence with a full-day session in Wilmington, Delaware on September 23, followed by sessions at the Philadelphia Navy Yard on September 24-26. The meeting will adjourn with an afternoon session on September 26 at the Delaware River Port Authority in Camden, New Jersey. Governor Markell (Delaware), Governor Corbett (Pennsylvania) and Governor Christie (New Jersey) are scheduled to speak in their respective states. Topics to be discussed during the conference include energy, healthcare, manufacturing, life sciences and intellectual property, among others.

“We are a nation of innovators, and our entrepreneurs excel at the highest standards.  Office of Advocacy research shows that 94% of the US research and development firms in the physical, engineering, and life sciences fields are small businesses,” said Dr. Winslow Sargeant, Chief Counsel for the SBA Office of Advocacy. “Next week, I am touring one of these firms, Iroko Pharmaceuticals.  For Iroko to remain competitive in our global economy, we must make sure the government works in tandem with its needs.  I look forward to learning more about how Advocacy’s efforts can help Iroko move America’s small business economy forward through innovation in the life sciences sector.”

About the Office of Advocacy Innovation Initiative

In 2012, the Office of Advocacy Innovation Initiative started with a symposium in Seattle, Washington.  The Innovation Initiative is a national dialogue discussing the importance of moving our small business economy forward through innovation.  The conversation focuses on the specific needs and concerns faced by high growth companies and entrepreneurs. These innovative businesses face different challenges in starting, maintaining and growing their operations than do other types of small businesses. This week the dialogue continues in Wilmington, Delaware; Philadelphia, Pennsylvania; and Camden, New Jersey.   Prior to this week’s event, Advocacy’s 10 Regional Advocates have been facilitating these conversations throughout the country with America’s small businesses.  Through these events, Chief Counsel Dr. Winslow Sargeant is able to relay this important feedback to the White House, Congress and federal agencies.

About Iroko Pharmaceuticals, LLC

Iroko is a global specialty pharmaceutical company, based in Philadelphia, dedicated to advancing the science of analgesia. The company acquires, develops and globally commercializes currently marketed products. In addition to the Iroko products that are marketed worldwide, the company has a robust pipeline of late-stage submicron NSAID product candidates. For more information, visit www.iroko.com.

About Phoenix IP Ventures

A fully-integrated Private Equity and Venture Capital Fund which specializes in life sciences, principally in the pharmaceutical sector, the Firm acquires intellectual property protected assets that meet its criteria for value maximization. Phoenix IP Ventures works in collaboration with major players in the financial community to scale its own proprietary investments in transactions identified and managed by the Firm.

Contacts:

Jessica Donnelly for Iroko Pharmaceuticals, LLC, 212-798-9819

Lisa Gray, Phoenix IP Ventures, 267-765-3233